All In Biotech

NDA 021197 · Emd Serono INC

Cetrotide

Cetrorelix Acetate · Subcutaneous

Novel

Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 11, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

117

27 Phase 3, 6 recruiting

FAERS reports

634

439 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2025.

INDICATIONS AND USAGE Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 11, 2000 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
2 products under this application
  • CETROTIDE · CETRORELIX ACETATE EQ 3MG BASE/VIAL · POWDER, SUBCUTANEOUS · Discontinued
  • CETROTIDE · CETRORELIX ACETATE EQ 0.25MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetrorelix" as an intervention, any sponsor and status, largest first.

All 117 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome136
  • drug ineffective45
  • premature ovulation41
  • abortion spontaneous39
  • abdominal distension30
  • off label use29
  • ascites28
  • abdominal pain26
  • condition aggravated25
  • nausea24
  • drug interaction21
  • generalised tonic-clonic seizure21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20064
20078
20086
200916
20108
201117
201218
201316
201414
201533
201627
201755
201858
201994
202058
202134
202231
202332
202433
202530
202640

Recalls

1 FDA enforcement reports for this application.

  • Jun 29, 2020 · Class II · Terminated

    Defective Container: Market complaints of missing rubber stoppers from drug vial. Missing rubber stoppers could lead to lack of sterility assurance.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 138 on PubMed

Sponsor: Emd Serono INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.